A critical analysis of the interpretation of biochemical failure in surgically treated patients using the American Society for Therapeutic Radiation and Oncology criteria

Journal of Urology

Volumn 168, Issue 4 I, 2002, Pages 1419-1422

  Gretzer, Matthew B ^a   Trock, Bruce J ^a   Han, Misop ^a   Walsh, Patrick C ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Prostate specific antigen; Prostatic neoplasms; Recurrence, prostatectomy, radiotherapy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; ARTICLE; BIOCHEMISTRY; CANCER LOCALIZATION; CONTROLLED STUDY; DATA ANALYSIS; FOLLOW UP; HORMONAL THERAPY; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; ONCOLOGY; PERIOPERATIVE PERIOD; PRIORITY JOURNAL; PROBABILITY; PROSPECTIVE STUDY; PROSTATE CARCINOMA; PROSTATECTOMY; RECURRENT DISEASE; RETROSPECTIVE STUDY; SURGICAL TECHNIQUE; TIME; TREATMENT FAILURE; UNITED STATES;

EID: 0036783942     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0022-5347(05)64464-3     Document Type: Article

References (23)

1. Era specific biochemical recurrence-free survival following radical prostatectomy for clinically localized prostate cancer
2. The value of serum prostate specific antigen determinations before and after radical prostatectomy
3. Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy
4. The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy
5. Consensus statement: Guidelines for PSA following radiation therapy
6. Prostate specific antigen-monitored combination radiotherapy for patients with prostate cancer. I-125 implant followed by external-beam radiation
7. Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: The relationship between nadir level and disease-free survival
8. The PSA nadir that indicates potential cure after radiotherapy for prostate cancer
9. Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma
10. Modern prostate brachytherapy. Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up
11. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer
12. Brachytherapy for clinically localized prostate cancer
13. Comparison of radical prostatectomy and iodine 125 interstitial radiotherapy for the treatment of clinically localized prostate cancer: A 7-year biochemical (PSA) progression analysis
14. Defining prostate specific antigen progression after radical prostatectomy: What is the most appropriate cut point?
15. A standard definition of disease freedom is needed for prostate cancer: Undetectable prostate specific antigen compared with the American Society of Therapeutic Radiology and Oncology consensus definition
16. Caution in interpreting biochemical control rates after treatment of prostate cancer: Length of follow-up influences results
17. The importance of adequate follow-up in defining treatment success after external beam irradiation for prostate cancer
18. Defining biochemical cure for prostate carcinoma patients treated with external beam radiation therapy
19. Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer
20. Temporary PSA rises and repeat prostate biopsies after brachytherapy
21. Scrutiny of the ASTRO consensus definition of biochemical failure in irradiated prostate cancer patients demonstrates its usefulness and robustness
22. The definition of biochemical failure in patients treated with definitive radiotherapy
23. Statistical aspects of evaluating treatment and prognostic factors for clinically localized prostate cancer